Analysis of Current Status and Influencing Factors of Inhaler Treatment Adherence Among COPD Patients. [PDF]
Int J Chron Obstruct Pulmon DisJin Z, Ba B, Zhang W, Yang Z, Wang X.
europepmc +1 more source
Clinical efficacy of Bufei Yishen and Qutan Tongluo Cream on the treatment of patients with stable chronic obstructive pulmonary disease. [PDF]
Front Med (Lausanne)Zhang H, Zhou Y, Song G.
europepmc +1 more source
Determinants of Medication Nonadherence Among Diverse Adults With Chronic Obstructive Pulmonary Disease. [PDF]
Chronic Obstr Pulm DisLaBedz SL +5 more
europepmc +1 more source
Clinical and Economic Evaluation of Fluticasone Furoate/Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol Therapy in Maintenance Treatment-Naive Patients with COPD in the US. [PDF]
Int J Chron Obstruct Pulmon DisShaikh A +6 more
europepmc +1 more source
Effect of Tiotropium on eye findings in the treatment of chronic obstructive pulmonary disease. [PDF]
BMC Pulm MedAksoy HB, Koç H.
europepmc +1 more source
Multivariate equivalence and component-wise superiority tests for paired samples. [PDF]
J Biopharm StatHu Y, Chinchilli VM.
europepmc +1 more source
Related searches:
Tiotropium bromide is an anticholinergic bronchodilator that antagonises muscarinic M(1), M(2) and M(3) receptors. It dissociates more slowly from M(1) receptors and, importantly, from M(3) receptors (which are located in bronchial smooth muscle) than from M(2) receptors and subsequently has a long duration of action permitting once-daily ...
Karen M, Hvizdos, Karen L, Goa
+6 more sources
Tiotropium bromide is a novel, inhaled, once-daily anticholinergic bronchodilator that has recently been approved in the United States for use in patients with COPD. Its unique feature is the persistence of bronchodilation for > 24 h due to prolonged M(3) muscarinic receptor blockade.
Cynthia Mundy, Peter Kirkpatrick
openaire +3 more sources
Formoterol and Tiotropium Compared With Tiotropium Alone for Treatment of COPD
COPD: Journal of Chronic Obstructive Pulmonary Disease, 2009 Combined use of beta(2)-agonists and anticholinergic bronchodilators may have complementary benefits in patients with chronic obstructive pulmonary disease (COPD). The objective of this study was to compare combination treatment with formoterol (FORM) plus tiotropium (TIO) versus treatment with TIO alone in patients with COPD. In this active-controlled,
Donald Tashkin
exaly +3 more sources